Rize Oncology Inc.
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -8.14% | 41.89% | 7.71% | -50.94% | -56.05% |
| Total Depreciation and Amortization | -85.25% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -80.73% | 1,234.29% | -80.11% | -3.83% | 1,063.16% |
| Change in Net Operating Assets | 7.66% | -251.43% | 9,871.43% | 100.62% | -253.76% |
| Cash from Operations | -2,056.49% | 95.58% | 22.47% | -6.36% | -263.43% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 214.29% | -93.69% | -73.88% | 2,600.00% | 96.77% |
| Miscellaneous Cash Flow Adjustments | -- | 100.00% | -- | -- | -- |
| Net Change in Cash | -244.09% | 163.08% | 9.29% | 5.92% | -284.53% |